Filing Flows › Gyre Therapeutics (GYRE) › Q2 2026 › vs Q1 2026
Gyre Therapeutics (GYRE) Q2 2026 vs Q1 2026 (quarter over quarter)
Gyre Therapeutics's revenue rose $6.6M (+29%) from $22.5M in Q1 2026 to $29.1M in Q2 2026.
Gyre Therapeutics, Q2 2026: revenue $29.1M (-2% year over year), operating margin -49.3%, net loss $23.0M, operating cash flow −$16.7M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $29.1M | $22.5M | $6.6M | +29% |
| Income tax benefit | $164K | −$621K | $785K | — |
| Net loss | $23.0M | $9.9M | $13.1M | +133% |
| Costs & expenses | $52.3M | $32.5M | $19.8M | +61% |
| Operating costs | $43.5M | $31.9M | $11.6M | +36% |
| Interest & other, net | $8.8M | −$118K | $8.9M | — |
| Cost of revenue | $2.2M | $1.2M | $982K | +80% |
| Other operating costs | $33.4M | $2.6M | $30.8M | 13× |
| Operating cash sources | $23.0M | $9.9M | $13.1M | +133% |
| Depreciation & amortization | $1.5M | $672K | $811K | +121% |
| Share-based compensation | $2.1M | $2.6M | −$508K | -20% |
| Working capital & other | $2.7M | $9.8M | −$7.1M | -72% |
| Cash used in operations | $16.7M | −$3.2M | $19.9M | — |
| Net loss absorbed | $23.0M | $9.9M | $13.1M | +133% |
Questions
How much did Gyre Therapeutics's revenue grow quarter over quarter in Q2 2026?
Gyre Therapeutics's revenue rose $6.6M (+29%) from $22.5M in Q1 2026 to $29.1M in Q2 2026.